CycleCue

CycleCue CycleCue is a modern menstrual and pregnancy tracking app designed to help women stay informed �

'Period scooping' on TikTok risks spreading harmful myths about menstruation. From unsupported claims about pelvic exerc...
09/11/2026

'Period scooping' on TikTok risks spreading harmful myths about menstruation. From unsupported claims about pelvic exercises to the dangers of douching, knowledge matters. Menstrual education is key. Choose menstrual health apps for accurate, secure insights. Which resources do you trust?

Significant investments in women's health—are they creating tangible changes? Delve into what our health systems must do...
07/11/2026

Significant investments in women's health—are they creating tangible changes? Delve into what our health systems must do to generate real impact.

Clue's latest feature, 'Get Care,' is designed to link its 100 million users in the US, UK, and Germany with healthcare ...
15/10/2026

Clue's latest feature, 'Get Care,' is designed to link its 100 million users in the US, UK, and Germany with healthcare providers, as covered by Femtech Insider. This free initiative bridges personal health insights and clinical care, initially focusing on contraception, conception, and perimenopause, with weight management and menopause care on the horizon.

Why This Matters: Harnessing Data for Health Decisions

'Get Care' marks a transformative step in aligning personal health data with medical consultations. Navigating complex healthcare landscapes, Clue simplifies the link between individual data and professional care. It's not just about collecting data—it's about using it to advocate for and obtain the right treatment.

Expanding Access with Caution

Clue's expanded services reflect a commitment to addressing women's broader health needs. Collaborations with partners like Novo Nordisk strengthen this initiative's resource pool and credibility. Yet, safeguarding user trust through strong data privacy safeguards while working with external partners is pivotal. Currently, clarity on privacy measures is lacking, which users may find concerning.

Cultivating Trust Through Partnerships

Clue's partnership network ensures that users receive high-quality care from vetted providers such as TwentyEight Health. These alliances lay the groundwork for seamless transformation of health insights into actionable medical advice, enhancing informed and efficient healthcare journeys.

Future Challenges and Opportunities

The real impact of 'Get Care' lies in how well personal health insights integrate into clinical practice. While initial steps show promise, the true test will be its ex*****on and user adoption. Key watch points include maintaining data privacy and expanding provider reach across regions.

By offering users clear ways to apply their health data practically, 'Get Care' might revolutionise women's health management. Keeping an eye on these developments could set new industry benchmarks.

Full story from Femtech Insider: https://femtechinsider.com/clue-launches-free-get-care-initiative-connecting-users-to-womens-health-specialists/

'sHealth

Collective X Health (CX) has secured a $3.2 million pre-seed funding round, specifically targeting the gender data gap i...
14/10/2026

Collective X Health (CX) has secured a $3.2 million pre-seed funding round, specifically targeting the gender data gap in women's health research. This funding is key to creating evidence-based insights for menstrual and reproductive health, historically skewed by reliance on male-centric data. The shift matters: cycle predictions and fertility tracking can now reflect true female physiology.

Why This Funding is Vital
Historically, ignoring women in health research has perpetuated a significant data void. Collective X’s funding, highlighted by F**t Insider, directly addresses this issue, promoting essential female-focused research. Dr. Stacy Sims, CX co-founder, underscores the risks of using male data for women's health—leading to misdiagnosis and inadequate care. This funding enables CX to bridge these gaps, bringing forward health insights grounded in female-centric evidence.

Innovative B2B Model
CX introduces an API offering research-driven insights, creating a standardised evidence layer for health applications. This approach transforms how companies incorporate menstrual and reproductive health data, setting new standards in consumer health apps. Businesses gain access to a solid base of thoroughly vetted insights, enabling the development of trustworthy health tools.

Tackling Historical Data Deficiency
Before 1993, the NIH largely ignored female-focused studies, skewing perceptions of women's health. CX, as noted by F**t Insider, aims to redress this by basing its intelligence on peer-reviewed research centered on female bodies. CX's entry into this formerly neglected area isn’t just academic; it's a revolutionary approach with the potential to significantly improve health outcomes. By addressing bias, women's health products can more precisely address real-world needs, achieving a precision absent for generations.

This funding and CX’s strategic mission are set to drive a transformative shift in women’s health insights. As they grow their research and partnerships, this initiative could fundamentally reshape health technology and product development for women.

What do you think this funding means for women's health research? Will this drive major changes in technology and application development?

Full story from F**t Insider: https://insider.fitt.co/press-release/collective-x-health-launches-with-a-3-2-million-pre-seed-round-to-close-the-womens-health-data-gap/

Google’s partnership with Flo Health, reported by PYMNTS.com, seeks to merge menstrual and health metrics—providing user...
14/10/2026

Google’s partnership with Flo Health, reported by PYMNTS.com, seeks to merge menstrual and health metrics—providing users with detailed insights. Yet, this raises pressing concerns about consent and personal data security.

The Balance of Integration and Autonomy
Merging sensitive health data requires a solid consent framework. While Google claims the syncing will empower users with a holistic health view, the details of managing consent are unknown. User control over data sharing is vital for trust.

Data Security: A Pillar of Trust
According to PYMNTS.com, users can sync Flo Health with Google Health metrics next year. However, Google's data protection measures remain unspecified. Robust security protocols are essential to prevent privacy breaches and ensure compliance.

The Trust Equation
Tech companies must earn user trust, especially when venturing into health. This partnership could affect privacy perceptions, with users keenly watching how tech giants handle personal health data.

What Lies Ahead?
As Google and Flo advance, the partnership's success may rely on transparency and security standards. Addressing these will be critical to user confidence and acceptance.

Discussion Prompt
How do you see the balance between personalised health insights and data privacy? Is integration a risk or an opportunity?

Full story from PYMNTS.com: https://www.pymnts.com/healthcare/2026/google-launches-womens-health-partnership-and-new-fitbit/

Ribupatide, a GLP-1/GIP dual receptor agonist, shows promise in treating PMOS with significant weight loss and improved ...
05/10/2026

Ribupatide, a GLP-1/GIP dual receptor agonist, shows promise in treating PMOS with significant weight loss and improved menstrual regularity. However, the trial also exposes a gap in PMOS-specific drug development. Future research on ribupatide's dual-action therapy offers hope for comprehensive PMOS management. Follow us for continued updates on menstrual health insights.

Could GLP-1 therapies signal a breakthrough in menstrual health management? Ribupatide's potential to aid weight loss an...
04/10/2026

Could GLP-1 therapies signal a breakthrough in menstrual health management? Ribupatide's potential to aid weight loss and enhance menstrual cycle regularity offers a promising direction for PMOS treatment. Recent trial results hint at significant impacts on drug development and patient outcomes.

GLP-1 therapies might soon revolutionise menstrual health management—a critical shift towards patient-centred outcomes i...
03/10/2026

GLP-1 therapies might soon revolutionise menstrual health management—a critical shift towards patient-centred outcomes in reproductive health.

Kailera Therapeutics and Hengrui Pharma are at the forefront with their GLP-1/GIP candidate, ribupatide. BioSpace reports that their recent mid-stage trial showed ribupatide offering dual benefits for women with polyendocrine metabolic ovarian syndrome (PMOS): notable weight loss and improved menstrual cycle regularity. This dual impact is significant as it tackles both obesity and menstrual irregularities, which are often linked in PMOS.

Despite these encouraging findings, a sizeable gap persists in dedicated PMOS therapies. Many women turn to off-label GLP-1 drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound, highlighting the market's unmet needs. This trend challenges regulators and healthcare providers to adapt to emerging evidence and real-world patient practices.

The drug development landscape for PMOS is notably sparse. Few firms focus on this condition, affecting many women, raising questions about research priorities in the pharmaceutical sector. Ribupatide's trial might spark change, encouraging more targeted innovation in this area.

Unanswered questions include the long-term effects of ribupatide on reproductive health, the trial's applicability to broader populations, and the path to wider adoption or regulatory approval.

As we explore these developments, what are the key priorities for advancing reproductive health solutions?

Full study from BioSpace: https://www.biospace.com/drug-development/kailera-hengruis-glp-1-gip-candidate-delivers-weight-menstrual-benefits-to-women-with-pmos

FLORA and Clue are revolutionising how menstrual and fertility data serve women's health, focusing on intuitive design t...
29/09/2026

FLORA and Clue are revolutionising how menstrual and fertility data serve women's health, focusing on intuitive design to transform insights into action. Yet, data privacy and user-centric questions linger. Their answers will define the future of health tech integration.

Yahoo Health reports that medications like semaglutide may affect menstrual cycles, with links to heavy bleeding and mis...
27/09/2026

Yahoo Health reports that medications like semaglutide may affect menstrual cycles, with links to heavy bleeding and missed ovulation. No causal link is confirmed yet, but these findings prompt reconsideration of how tracking apps handle predictions. Insights from FDA reports are essential for improving prediction accuracy and user trust. Keep informed about health factors that may influence your cycle.

Address

Sandton

Alerts

Be the first to know and let us send you an email when CycleCue posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to CycleCue:

Shortcuts

Share